1
|
Shi Y, Wang Q, Rong J, Ren J, Song X, Fan X, Shen M, Xia Y, Wang N, Liu Z, Hu Q, Ye T, Yu L. Synthesis and biological evaluation of (1,2,4)triazole[4,3-a]pyridine derivatives as potential therapeutic agents for concanavalin A-induced hepatitis. Eur J Med Chem 2019; 179:182-195. [PMID: 31254920 DOI: 10.1016/j.ejmech.2019.06.025] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2019] [Revised: 05/28/2019] [Accepted: 06/08/2019] [Indexed: 02/06/2023]
Abstract
A series of (1,2,4)triazole[4,3-a]pyridine (TZP) derivatives have been designed and synthesized. Compound 8d was identified as having the most potent inhibitory activity on NO release in response to lipopolysaccharide (LPS) stimulation and inhibition of the migration induced by MCP-1 protein on RAW264.7 macrophages. Based on the screening data, an immunofluorescence assay and a real-time qPCR assay were conducted, indicating that compound 8d suppressed NF-κB p65 translocation and expression of inflammatory genes by concanavalin A (Con A)-induced RAW264.7 macrophages. More importantly, 8d also exhibited potent efficacy, alleviating Con A-induced hepatitis by downregulating the levels of plasma alanine transaminase (ALT), aspartate transaminase (AST) and inflammatory infiltration in a mouse autoimmune hepatitis (AIH) model. In addition, the flow cytometry (FCM) data showed that compound 8d inhibited the accumulation of MDSCs in the liver of Con A-induced mice. These findings raise the possibility that compound 8d might serve as a potential agent for the treatment of AIH.
Collapse
Affiliation(s)
- Yaojie Shi
- Laboratory of Liver Surgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, 610041, China
| | - Qianqian Wang
- Laboratory of Liver Surgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, 610041, China
| | - Juan Rong
- Laboratory of Liver Surgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, 610041, China
| | - Jing Ren
- Laboratory of Liver Surgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, 610041, China
| | - Xuejiao Song
- Research Center for Public Health & Preventive Medicine, West China School of Public Health & Healthy Food Evaluation Research Center/No.4 West China Teaching Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
| | - Xiaoli Fan
- Division of Digestive Diseases, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, China
| | - Mengyi Shen
- Division of Digestive Diseases, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, China
| | - Yong Xia
- Laboratory of Liver Surgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, 610041, China
| | - Ningyu Wang
- School of Life Science and Engineering, Southwest JiaoTong University, Chengdu, Sichuan, 611756, China
| | - Zhihao Liu
- Laboratory of Liver Surgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, 610041, China
| | - Quanfang Hu
- Laboratory of Liver Surgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, 610041, China
| | - Tinghong Ye
- Laboratory of Liver Surgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, 610041, China.
| | - Luoting Yu
- Laboratory of Liver Surgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, 610041, China.
| |
Collapse
|
2
|
Expanding the chemical space of sp3-enriched 4,5-disubstituted oxazoles via synthesis of novel building blocks. Chem Heterocycl Compd (N Y) 2019. [DOI: 10.1007/s10593-019-02475-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
3
|
Zribi L, Zribi F, Marco-Contelles J, Chabchoub F, Ismaili L. Facile one-pot synthesis of new [1,2,4]triazolo[1,5-a]pyridine derivatives by ultrasonic irradiation. SYNTHETIC COMMUN 2017. [DOI: 10.1080/00397911.2017.1357078] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Lazhar Zribi
- Laboratory of Applied Chemistry, Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax, University of Sfax, Sfax, Tunisia
| | - Fathi Zribi
- Laboratory of Applied Chemistry, Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax, University of Sfax, Sfax, Tunisia
| | | | - Fakher Chabchoub
- Laboratory of Applied Chemistry, Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax, University of Sfax, Sfax, Tunisia
| | - Lhassane Ismaili
- Laboratoire de Chimie Organique et Thérapeutique, Neurosciences Intégratives et Cliniques, University of Bourgogne Franche-Comté, Besançon, France
| |
Collapse
|
4
|
Zheng H, Wang K, Zhang W, Liu R. Selenium Dioxide–Mediated Synthesis of Fused 1,2,4-Triazoles as Cytotoxic Agents. SYNTHETIC COMMUN 2015. [DOI: 10.1080/00397911.2015.1111384] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Tiwari DK, Pogula J, Tiwari DK. A general and practical route to 4,5-disubstituted oxazoles using acid chlorides and isocyanides. RSC Adv 2015. [DOI: 10.1039/c5ra07668d] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
An efficient and mild method for the synthesis of 4,5-di-substituted oxazolesvia[3 + 2] cycloaddition reaction of isocyanides and acid chlorides is reported.
Collapse
Affiliation(s)
- Dipak Kumar Tiwari
- Inorganic and Physical Chemistry Division
- CSIR-Indian Institute of Chemical Technology
- Hyderabad-500007
- India
| | - Jaya Pogula
- Inorganic and Physical Chemistry Division
- CSIR-Indian Institute of Chemical Technology
- Hyderabad-500007
- India
| | - Dharmendra Kumar Tiwari
- Inorganic and Physical Chemistry Division
- CSIR-Indian Institute of Chemical Technology
- Hyderabad-500007
- India
| |
Collapse
|
6
|
Arora VK, Philip T, Huang S, Shu YZ. A Novel Ring Oxidation of 4- or 5-Substituted 2H-Oxazole to Corresponding 2-Oxazolone Catalyzed by Cytosolic Aldehyde Oxidase. Drug Metab Dispos 2012; 40:1668-76. [DOI: 10.1124/dmd.112.044545] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
|
7
|
Aiguadé J, Balagué C, Carranco I, Caturla F, Domínguez M, Eastwood P, Esteve C, González J, Lumeras W, Orellana A, Preciado S, Roca R, Vidal L, Vidal B. Novel triazolopyridylbenzamides as potent and selective p38α inhibitors. Bioorg Med Chem Lett 2012; 22:3431-6. [DOI: 10.1016/j.bmcl.2012.03.099] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2012] [Revised: 03/23/2012] [Accepted: 03/28/2012] [Indexed: 11/25/2022]
|
8
|
Liu C, Lin J, Wrobleski ST, Lin S, Hynes J, Wu H, Dyckman AJ, Li T, Wityak J, Gillooly KM, Pitt S, Shen DR, Zhang RF, McIntyre KW, Salter-Cid L, Shuster DJ, Zhang H, Marathe PH, Doweyko AM, Sack JS, Kiefer SE, Kish KF, Newitt JA, McKinnon M, Dodd JH, Barrish JC, Schieven GL, Leftheris K. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases. J Med Chem 2010; 53:6629-39. [PMID: 20804198 DOI: 10.1021/jm100540x] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The discovery and characterization of 7k (BMS-582949), a highly selective p38α MAP kinase inhibitor that is currently in phase II clinical trials for the treatment of rheumatoid arthritis, is described. A key to the discovery was the rational substitution of N-cyclopropyl for N-methoxy in 1a, a previously reported clinical candidate p38α inhibitor. Unlike alkyl and other cycloalkyls, the sp(2) character of the cyclopropyl group can confer improved H-bonding characteristics to the directly substituted amide NH. Inhibitor 7k is slightly less active than 1a in the p38α enzymatic assay but displays a superior pharmacokinetic profile and, as such, was more effective in both the acute murine model of inflammation and pseudoestablished rat AA model. The binding mode of 7k with p38α was confirmed by X-ray crystallographic analysis.
Collapse
Affiliation(s)
- Chunjian Liu
- Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Eda H, Zhang J, Keith RH, Michener M, Beidler DR, Monahan JB. Macrophage-colony stimulating factor and interleukin-34 induce chemokines in human whole blood. Cytokine 2010; 52:215-20. [PMID: 20829061 DOI: 10.1016/j.cyto.2010.08.005] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2010] [Revised: 05/31/2010] [Accepted: 08/16/2010] [Indexed: 12/20/2022]
Abstract
The aim of this study is to investigate if macrophage-colony stimulating factor (M-CSF) or interleukin-34 (IL-34) induces cytokines or chemokines using human whole blood (HWB) and if an M-CSF- or IL-34-induced cytokine or chemokine production from HWB is inhibited by soluble M-CSF receptor or c-FMS kinase inhibitors. Among eight cytokines or growth factors tested, only IL-6 level was increased by up to 6-fold by M-CSF or IL-34 in HWB. In contrast, chemokine levels (IP-10/CXCL10, IL-8/CXCL8, and MCP-1/CCL2) were dramatically increased by M-CSF or IL-34 in HWB while exhibiting a large variation among donors. Variability of the MCP-1 signal induced by M-CSF or IL-34 was relatively less among donors compared to the IP-10 and IL-8 signals. The elevation of these chemokine levels was significantly decreased by soluble M-CSF receptor, indicating the elevation of these chemokines was mediated by M-CSF or IL-34. Furthermore, GW2580, a c-FMS kinase inhibitor, inhibited the induction of MCP-1 by M-CSF or IL-34 in a concentration dependent manner. These indicate MCP-1 is the most appropriate chemokine target for a chemokine release assay to evaluate the potency of c-FMS kinase inhibitors and MCP-1 release assay using HWB would be useful, relevant tool for translational pharmacology of c-FMS kinase inhibitors.
Collapse
Affiliation(s)
- Hiroyuki Eda
- Discovery Biology, Global Research and Development, St. Louis Laboratories, Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA.
| | | | | | | | | | | |
Collapse
|
10
|
Ratkova EL, Chuev GN, Sergiievskyi VP, Fedorov MV. An Accurate Prediction of Hydration Free Energies by Combination of Molecular Integral Equations Theory with Structural Descriptors. J Phys Chem B 2010; 114:12068-79. [DOI: 10.1021/jp103955r] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Ekaterina L. Ratkova
- The Max Planck Institute for Mathematics in the Sciences, Inselstrasse 22, Leipzig, 04103, Germany, and Institute of Theoretical and Experimental Biophysics, Russian Academy of Science, Pushchino, Moscow Region, 142290, Russia
| | - Gennady N. Chuev
- The Max Planck Institute for Mathematics in the Sciences, Inselstrasse 22, Leipzig, 04103, Germany, and Institute of Theoretical and Experimental Biophysics, Russian Academy of Science, Pushchino, Moscow Region, 142290, Russia
| | - Volodymyr P. Sergiievskyi
- The Max Planck Institute for Mathematics in the Sciences, Inselstrasse 22, Leipzig, 04103, Germany, and Institute of Theoretical and Experimental Biophysics, Russian Academy of Science, Pushchino, Moscow Region, 142290, Russia
| | - Maxim V. Fedorov
- The Max Planck Institute for Mathematics in the Sciences, Inselstrasse 22, Leipzig, 04103, Germany, and Institute of Theoretical and Experimental Biophysics, Russian Academy of Science, Pushchino, Moscow Region, 142290, Russia
| |
Collapse
|
11
|
Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: Part 2. Bioorg Med Chem Lett 2010; 20:2435-7. [DOI: 10.1016/j.bmcl.2010.03.022] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2010] [Revised: 02/27/2010] [Accepted: 03/04/2010] [Indexed: 11/21/2022]
|
12
|
Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition. Bioorg Med Chem Lett 2010; 20:469-73. [DOI: 10.1016/j.bmcl.2009.11.114] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2009] [Revised: 11/20/2009] [Accepted: 11/23/2009] [Indexed: 11/18/2022]
|
13
|
Aston NM, Bamborough P, Buckton JB, Edwards CD, Holmes DS, Jones KL, Patel VK, Smee PA, Somers DO, Vitulli G, Walker AL. p38α Mitogen-Activated Protein Kinase Inhibitors: Optimization of a Series of Biphenylamides to Give a Molecule Suitable for Clinical Progression. J Med Chem 2009; 52:6257-69. [DOI: 10.1021/jm9004779] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Nicola M. Aston
- GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2NY, U.K
| | - Paul Bamborough
- GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2NY, U.K
| | - Jacqueline B. Buckton
- GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2NY, U.K
| | - Christopher D. Edwards
- GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2NY, U.K
| | - Duncan S. Holmes
- GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2NY, U.K
| | - Katherine L. Jones
- GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2NY, U.K
| | - Vipulkumar K. Patel
- GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2NY, U.K
| | - Penny A. Smee
- GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2NY, U.K
| | - Donald O. Somers
- GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2NY, U.K
| | - Giovanni Vitulli
- GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2NY, U.K
| | - Ann L. Walker
- GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2NY, U.K
| |
Collapse
|
14
|
Armen RS, Chen J, Brooks CL. An Evaluation of Explicit Receptor Flexibility in Molecular Docking Using Molecular Dynamics and Torsion Angle Molecular Dynamics. J Chem Theory Comput 2009; 5:2909-2923. [PMID: 20160879 DOI: 10.1021/ct900262t] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Incorporating receptor flexibility into molecular docking should improve results for flexible proteins. However, the incorporation of explicit all-atom flexibility with molecular dynamics for the entire protein chain may also introduce significant error and "noise" that could decrease docking accuracy and deteriorate the ability of a scoring function to rank native-like poses. We address this apparent paradox by comparing the success of several flexible receptor models in cross-docking and multiple receptor ensemble docking for p38α mitogen-activated protein (MAP) kinase. Explicit all-atom receptor flexibility has been incorporated into a CHARMM-based molecular docking method (CDOCKER) using both molecular dynamics (MD) and torsion angle molecular dynamics (TAMD) for the refinement of predicted protein-ligand binding geometries. These flexible receptor models have been evaluated, and the accuracy and efficiency of TAMD sampling is directly compared to MD sampling. Several flexible receptor models are compared, encompassing flexible side chains, flexible loops, multiple flexible backbone segments, and treatment of the entire chain as flexible. We find that although including side chain and some backbone flexibility is required for improved docking accuracy as expected, docking accuracy also diminishes as additional and unnecessary receptor flexibility is included into the conformational search space. Ensemble docking results demonstrate that including protein flexibility leads to to improved agreement with binding data for 227 active compounds. This comparison also demonstrates that a flexible receptor model enriches high affinity compound identification without significantly increasing the number of false positives from low affinity compounds.
Collapse
Affiliation(s)
- Roger S Armen
- Department of Chemistry, 930 N. University Ave, University of Michigan, Ann Arbor, MI 48109
| | | | | |
Collapse
|
15
|
Lumeras W, Caturla F, Vidal L, Esteve C, Balagué C, Orellana A, Domínguez M, Roca R, Huerta JM, Godessart N, Vidal B. Design, Synthesis, and Structure−Activity Relationships of Aminopyridine N-Oxides, a Novel Scaffold for the Potent and Selective Inhibition of p38 Mitogen Activated Protein Kinase. J Med Chem 2009; 52:5531-45. [DOI: 10.1021/jm9008604] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
| | | | | | | | | | | | | | - Ramón Roca
- Department of Computational and Structural Drug Discovery
| | | | | | | |
Collapse
|
16
|
Primas N, Bouillon A, Lancelot JC, Rault S. Synthesis of 2-TIPS-oxazol-5-ylboronic acid pinacol ester: efficient route to 5-(het)aryloxazoles via Suzuki cross-coupling reaction. Tetrahedron 2009. [DOI: 10.1016/j.tet.2009.06.023] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
17
|
Comas H, Bernardinelli G, Swinnen D. A Straightforward, One-Pot Protocol for the Synthesis of Fused 3-Aminotriazoles. J Org Chem 2009; 74:5553-8. [DOI: 10.1021/jo9009084] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- Horacio Comas
- Chemistry Department, Merck Serono Geneva Research Center, 9 Chemin des Mines, 1202 Geneva, Switzerland
| | - Gérald Bernardinelli
- Laboratoire de Crystallographie, Université de Genève, 24 quai Ernest Ansermet, 1211 Geneva, Switzerland
| | - Dominique Swinnen
- Chemistry Department, Merck Serono Geneva Research Center, 9 Chemin des Mines, 1202 Geneva, Switzerland
| |
Collapse
|
18
|
2-Aminoimidazoles inhibitors of TGF-β receptor 1. Bioorg Med Chem Lett 2009; 19:912-6. [DOI: 10.1016/j.bmcl.2008.11.119] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2008] [Revised: 11/25/2008] [Accepted: 11/26/2008] [Indexed: 11/19/2022]
|
19
|
Shashi Nayana MR, Sekhar YN, Siva Kumari N, Mahmood SK, Ravikumar M. CoMFA and docking studies on triazolopyridine oxazole derivatives as p38 MAP kinase inhibitors. Eur J Med Chem 2008; 43:1261-9. [PMID: 17825954 DOI: 10.1016/j.ejmech.2007.07.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2007] [Revised: 07/06/2007] [Accepted: 07/09/2007] [Indexed: 11/25/2022]
Abstract
With the objective to design new chemical entities with enhanced inhibitory potencies against p38 MAP alpha kinase, the 3D-QSAR and Comparative Molecular Field Analysis (CoMFA) studies were carried out on triazolopyridine oxazole compounds as inhibitors of these kinase is presented here. The developed model gave q(2) value of 0.707 and r(2) value of 0.942 for CoMFA. The high leave-one-out (LOO) cross-validated correlation coefficient q(2) reveals that the model is a useful tool for the prediction of test set of 19 compounds that were not included in the training set of 55 compounds. The results not only lead to better understanding of structural requirements of p38 alpha inhibitors but also can help in the design of new potent inhibitors. The binding mode of the compounds at the active site of p38 MAP alpha kinase was explored using Glide docking program and hydrogen-bonding interactions were observed between the inhibitors and the target. The details of amino acid interactions of the active site are discussed briefly and correlated with the contour plots.
Collapse
Affiliation(s)
- M Ravi Shashi Nayana
- Bioinformatics Division, Environmental Microbiology Lab, Department of Botany, Osmania University, Hyderabad 500 007, A.P., India
| | | | | | | | | |
Collapse
|
20
|
Benzothiazole based inhibitors of p38alpha MAP kinase. Bioorg Med Chem Lett 2008; 18:1874-9. [PMID: 18296051 DOI: 10.1016/j.bmcl.2008.02.011] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2007] [Revised: 02/04/2008] [Accepted: 02/07/2008] [Indexed: 11/20/2022]
Abstract
Rational design, synthesis, and SAR studies of a novel class of benzothiazole based inhibitors of p38alpha MAP kinase are described. The issue of metabolic instability associated with vicinal phenyl, benzo[d]thiazol-6-yl oxazoles/imidazoles was addressed by the replacement of the central oxazole or imidazole ring with an aminopyrazole system. The proposed binding mode of this new class of p38alpha inhibitors was confirmed by X-ray crystallographic studies of a representative inhibitor (6a) bound to the p38alpha enzyme.
Collapse
|
21
|
Filák L, Riedl Z, Egyed O, Czugler M, Hoang CN, Schantl JG, Hajós G. A new synthesis of the linearly fused [1,2,4]triazolo[1,5-b]isoquinoline ring. Observation of an unexpected Dimroth rearrangement. Tetrahedron 2008. [DOI: 10.1016/j.tet.2007.10.103] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Li B, Buzon RA, Zhang Z. Syntheses of 4,5-Disubstituted Oxazoles via Regioselective C-4 Bromination. Org Process Res Dev 2007. [DOI: 10.1021/op700176n] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Bryan Li
- Research API–Pharmaceutical Science, Pfizer Global Research and Development, Groton, Connecticut 06340, U.S.A
| | - Richard A. Buzon
- Research API–Pharmaceutical Science, Pfizer Global Research and Development, Groton, Connecticut 06340, U.S.A
| | - Zhijun Zhang
- Research API–Pharmaceutical Science, Pfizer Global Research and Development, Groton, Connecticut 06340, U.S.A
| |
Collapse
|